Ashwini Nadkarni, MD, of Mass General Brigham, discusses what’s new in the management of generalized anxiety disorder.

Ashwini Nadkarni, MD, of Mass General Brigham, discusses how the treatment landscape has changed in recent years for generalized anxiety disorder.

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap ...

Everyone has anxiety, but an anxiety disorder is another thing entirely. Here's what women need to know about worry gone wild ...

Dr Bradley N. Gaynes reflects on how the understanding and treatment of generalized anxiety disorder (GAD) has evolved over the past three decades. One major advance has been the improved ability to ...

Lily A. Brown, PhD, describes a patient with generalized anxiety disorder (GAD) who sought urgent consultation despite prior evaluations by multiple clinicians internationally. The patient’s continued ...

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new ...

Earlier this month, Definium Therapeutics reported results from a large U.S. healthcare claims study of more than 1.27 ...

Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...

Everyone has anxiety, but an anxiety disorder is another thing entirely. Here's what women need to know about worry gone wild ...

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.

New program provides expert psychiatric care for PMDD, perinatal mental health, perimenopause, menopause, postpartum ...